Biomarkers of Alzheimer disease

Archives of Neurology

Volumn 56, Issue 3, 1999, Pages 281-283

  Growdon, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; HUMAN; MOLECULAR GENETICS; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

EID: 0032991227     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.3.281     Document Type: Review

References (14)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
2. Growdon JH. Advances in the diagnosis of Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York, NY: John Wiley & Sons Inc: 1995: 139-153.
3. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus Report of the Working Group on molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 1998;19:109-116.
4. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈;4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
5. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ∈4 in Alzheimer's disease. Ann Neurol. 1996;39:62-70.
6. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E geno-type in the diagnosis of Alzheimer's disease. N Engl J Med. 1998;338: 506-511.
7. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Ann Rev Neurosci. 1994;17:489-517.
8. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997; 20:154-159.
9. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
10. Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The Dementias. Boston, Mass: Butterworth-Heinemann: 1998: 285-304.
11. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995; 38:643-648.
12. 1-42i 43. Ann Neurol. 1998;44:17-26.
13. de la Monte SM, Ghanbari K, Frey WH, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1997;100:3093-3104.
14. The National Institute of Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathologic assessment of Alzheimer's disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl 4):S1-S2.